0 Beoordelingen

ID

15287

Beschrijving

Phase Ib Dose-escalation, Phase II Study of LEE011 and Letrozole for Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02333370

Link

https://clinicaltrials.gov/show/NCT02333370

Trefwoorden

  1. 25-05-16 25-05-16 -
Geüploaded op

25 mei 2016

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :


    Geen commentaren

    U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

    Eligibility Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer NCT02333370

    Eligibility Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer NCT02333370

    Inclusion Criteria
    Beschrijving

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy (surgery and/or radiotherapy).
    Beschrijving

    Gender | Locally advanced breast cancer Recurrent | Advanced breast cancer metastatic | curative treatment | Curative Surgery | Therapeutic radiology procedure

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C0079399
    UMLS CUI [2,1]
    C3495949
    UMLS CUI [2,2]
    C2945760
    UMLS CUI [3,1]
    C3495917
    UMLS CUI [3,2]
    C1522484
    UMLS CUI [4]
    C1273390
    UMLS CUI [5]
    C1511562
    UMLS CUI [6]
    C1522449
    patient is postmenopausal.
    Beschrijving

    Postmenopausal state

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C0232970
    patient has a histologically and/or cytologically confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive breast cancer
    Beschrijving

    estrogen or progesterone receptor positive for breast cancer | Histology | Cytology

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C2367479
    UMLS CUI [2]
    C0344441
    UMLS CUI [3]
    C1305671
    patient has her2-negative breast cancer
    Beschrijving

    Human epidermal growth factor 2 negative carcinoma of breast

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C2316304
    patient has adequate bone marrow and organ function
    Beschrijving

    Bone Marrow physiological aspects | organ function

    Datatype

    boolean

    Alias
    UMLS CUI [1,1]
    C0005953
    UMLS CUI [1,2]
    C0031843
    UMLS CUI [2]
    C0678852
    Exclusion Criteria
    Beschrijving

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    patient who received any cdk4/6 inhibitor.
    Beschrijving

    CDK4/6 Inhibition

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C3899807
    patient has a known hypersensitivity to any of the excipients of lee011 or letrozole
    Beschrijving

    Hypersensitivity LEE011 Excipient | Hypersensitivity letrozole Excipient

    Datatype

    boolean

    Alias
    UMLS CUI [1,1]
    C0020517
    UMLS CUI [1,2]
    C2987342
    UMLS CUI [1,3]
    C0015237
    UMLS CUI [2,1]
    C0020517
    UMLS CUI [2,2]
    C0246421
    UMLS CUI [2,3]
    C0015237
    patients with inflammatory breast cancer.
    Beschrijving

    Inflammatory Breast Carcinoma

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C0278601
    patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer
    Beschrijving

    Advanced breast cancer | Cancer treatment Systemic | Hormone Therapy | Chemotherapy

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C3495917
    UMLS CUI [2,1]
    C0920425
    UMLS CUI [2,2]
    C0205373
    UMLS CUI [3]
    C0279025
    UMLS CUI [4]
    C0392920
    patient is currently using other anti-cancer therapy
    Beschrijving

    Cancer treatment Other

    Datatype

    boolean

    Alias
    UMLS CUI [1,1]
    C0920425
    UMLS CUI [1,2]
    C0205394
    patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
    Beschrijving

    major surgery | Investigational New Drugs | adverse effects Major

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C0679637
    UMLS CUI [2]
    C0013230
    UMLS CUI [3,1]
    C0001688
    UMLS CUI [3,2]
    C0205164
    patient who has received radiotherapy ≤ 4 weeks
    Beschrijving

    Therapeutic radiology procedure

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C1522449
    patient has a concurrent malignancy or malignancy within 3 years
    Beschrijving

    Malignant Neoplasms

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C0006826
    patient has metastases to the central nervous system (cns).
    Beschrijving

    CNS metastases

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C0686377
    patient has a known history of hiv infection
    Beschrijving

    HIV Infections

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C0019693
    other protocol-defined inclusion/exclusion criteria may apply
    Beschrijving

    Inclusion Other | Exclusion Criteria Other

    Datatype

    boolean

    Alias
    UMLS CUI [1,1]
    C1512693
    UMLS CUI [1,2]
    C0205394
    UMLS CUI [2,1]
    C0680251
    UMLS CUI [2,2]
    C0205394

    Similar models

    Eligibility Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer NCT02333370

    Name
    Type
    Description | Question | Decode (Coded Value)
    Datatype
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Gender | Locally advanced breast cancer Recurrent | Advanced breast cancer metastatic | curative treatment | Curative Surgery | Therapeutic radiology procedure
    Item
    women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy (surgery and/or radiotherapy).
    boolean
    C0079399 (UMLS CUI [1])
    C3495949 (UMLS CUI [2,1])
    C2945760 (UMLS CUI [2,2])
    C3495917 (UMLS CUI [3,1])
    C1522484 (UMLS CUI [3,2])
    C1273390 (UMLS CUI [4])
    C1511562 (UMLS CUI [5])
    C1522449 (UMLS CUI [6])
    Postmenopausal state
    Item
    patient is postmenopausal.
    boolean
    C0232970 (UMLS CUI [1])
    estrogen or progesterone receptor positive for breast cancer | Histology | Cytology
    Item
    patient has a histologically and/or cytologically confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive breast cancer
    boolean
    C2367479 (UMLS CUI [1])
    C0344441 (UMLS CUI [2])
    C1305671 (UMLS CUI [3])
    Human epidermal growth factor 2 negative carcinoma of breast
    Item
    patient has her2-negative breast cancer
    boolean
    C2316304 (UMLS CUI [1])
    Bone Marrow physiological aspects | organ function
    Item
    patient has adequate bone marrow and organ function
    boolean
    C0005953 (UMLS CUI [1,1])
    C0031843 (UMLS CUI [1,2])
    C0678852 (UMLS CUI [2])
    Item Group
    C0680251 (UMLS CUI)
    CDK4/6 Inhibition
    Item
    patient who received any cdk4/6 inhibitor.
    boolean
    C3899807 (UMLS CUI [1])
    Hypersensitivity LEE011 Excipient | Hypersensitivity letrozole Excipient
    Item
    patient has a known hypersensitivity to any of the excipients of lee011 or letrozole
    boolean
    C0020517 (UMLS CUI [1,1])
    C2987342 (UMLS CUI [1,2])
    C0015237 (UMLS CUI [1,3])
    C0020517 (UMLS CUI [2,1])
    C0246421 (UMLS CUI [2,2])
    C0015237 (UMLS CUI [2,3])
    Inflammatory Breast Carcinoma
    Item
    patients with inflammatory breast cancer.
    boolean
    C0278601 (UMLS CUI [1])
    Advanced breast cancer | Cancer treatment Systemic | Hormone Therapy | Chemotherapy
    Item
    patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer
    boolean
    C3495917 (UMLS CUI [1])
    C0920425 (UMLS CUI [2,1])
    C0205373 (UMLS CUI [2,2])
    C0279025 (UMLS CUI [3])
    C0392920 (UMLS CUI [4])
    Cancer treatment Other
    Item
    patient is currently using other anti-cancer therapy
    boolean
    C0920425 (UMLS CUI [1,1])
    C0205394 (UMLS CUI [1,2])
    major surgery | Investigational New Drugs | adverse effects Major
    Item
    patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
    boolean
    C0679637 (UMLS CUI [1])
    C0013230 (UMLS CUI [2])
    C0001688 (UMLS CUI [3,1])
    C0205164 (UMLS CUI [3,2])
    Therapeutic radiology procedure
    Item
    patient who has received radiotherapy ≤ 4 weeks
    boolean
    C1522449 (UMLS CUI [1])
    Malignant Neoplasms
    Item
    patient has a concurrent malignancy or malignancy within 3 years
    boolean
    C0006826 (UMLS CUI [1])
    CNS metastases
    Item
    patient has metastases to the central nervous system (cns).
    boolean
    C0686377 (UMLS CUI [1])
    HIV Infections
    Item
    patient has a known history of hiv infection
    boolean
    C0019693 (UMLS CUI [1])
    Inclusion Other | Exclusion Criteria Other
    Item
    other protocol-defined inclusion/exclusion criteria may apply
    boolean
    C1512693 (UMLS CUI [1,1])
    C0205394 (UMLS CUI [1,2])
    C0680251 (UMLS CUI [2,1])
    C0205394 (UMLS CUI [2,2])

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial